Vaccines
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Global vaccine market intelligence for pharma BD, investors & analysts. Stay ahead with critical regulatory updates & competitive insights.
Showing 1–12 of 21 articles
Quick answer
NovaPharmaNews Vaccines hub for FDA covers 21 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response
Amish Health Beliefs: Vaccines, Costs, and Pharma Strategy Insights
FDA Approves Ensitrelvir (XOCOVA) as First Oral Option for COVID-19 Post-Exposure Prophylaxis
STAT+: RFK Jr.’s second year: Vacancies, not vaccines
Ebola Response Shift: Trump Administration's New Playbook and Pharma Implications
STAT+ Pharmalittle: Lilly's 340B Hospital Threat, Ebola Vaccine Funding, and More
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19
How one state’s medical meal program lowered health care costs
Personalized mRNA Cancer Vaccines: A New Era for Melanoma Treatment
Biotech Movers: Moderna, Iovance, ALHC, and Summit Therapeutics in Focus
Trump's Executive Order on Childhood Vaccine Schedules: Impact on Pharmaceutical Companies
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.